NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

We all know why measuring tumor shrinkage is confounding in immunotherapy. In this trial the mOS for nGBM was 19.3mo vs 16.5mo in ECP and for rGBM it was 13.2mo vs. 7.8mo. 5 year survival was 13% vs. 5.7%. What exactly is difficult in determining what contribution the drug made?

How much contribution was made by:

. DCVax-L trial enrolling only patients with intent for near total resection while others enrolled partials and biopsies?

. DCVax-L only accepted about 35% of patients while other trials accepted many more

. Improvements in surgery over the years between the ECA arm patients and the DCVax-L trial.

. Improvements in subsequent care. Both Toms and Musella assert Optune helps patients live longer.

The problem is, how does anybody know?

EDIT: BTW, for rGBM, LL et all assert they do not know which patients were really rGBM. How can one compare patients who might be rGBM to those who are?